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Table 1
Comparison of Demographic Data, Mobilization Characteristics and Post
Transplant Outcome in Patients Using Meloxicam + G-CSF Compared with
Historical Controls
Variables Meloxicam +
GCSF (n ¼ 25)
G-CSF Alone
(n ¼ 50)
P
Value
Median age (yr) 51 (25-63) 50 (18-65) .902
Sex M:F 20:5 36:14 .577
Diagnosis
MM 15 (60%) 32 (64%)
NHL/HD 8 (32%) 14 (28%)
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Introduction: Although rituximab containing chemotherapy
regimens have improved response rates in B-cell lym-
phomas, a signiﬁcant percentage of patients will eventually
relapse. Autologous stem cell transplantation (Auto SCT) may
provide long-term remission in some of these patients. Tu-
mor contamination of harvested stem cell graft has been
postulated as a reason for relapse after Auto SCT. Single agent
rituximab has been used for in-vivo purging of CD20+ tumor
cells with positive results. In this study, we aimed to evaluate
whether use of rituximab based in-vivo purging is still
beneﬁcial in the era of universal use of rituximab containing
chemotherapy in patients with follicular (FL) or mantle cell
lymphoma (MCL).
Materials and Methods: Twenty consecutive patients with a
diagnosis of relapsed CD20+ FL or transplant eligible MCL
were included in this study. All patients received rituximab
containing chemotherapy. Restaging was done after
completion of chemotherapy and those with chemo-sensi-
tive disease (n¼14) were considered for Auto SCT. Polymer-
ase Chain Reaction (PCR) analysis for bcl2 and bcl1 were
done on apheresis products from patients with FL and MCL
respectively. In-vivo purging with single agent rituximab
was planned if any stem cell product were to be found PCR
positive prior to Auto SCT.
Results: A total of 19 patients were eligible for analysis. Pa-
tient characteristics are shown in the accompanying table.
The bcl-2/bcl-1 status of the graft was available in 14 patients
(FL; n¼10 and MCL; n¼4). The stem cell products in all 14
patients tested negative by PCR for both bcl2 (FL) and
bcl1(MCL). None of these patients required additional rit-
uximab treatment for in-vivo purging. Eleven patients (FL;
n¼7 and MCL; n¼4) underwent Auto SCT. Three patients
with FL opted for “Harvest and Hold” approach and delayed
transplantation. Median (range) PFS and OS of patients with
FL undergoing Auto SCT were 2 yrs. (9 mo-5 y) and 3 yrs. (2-5
y) and those with MCL were 3 yrs. (2-4y) and 4 yrs. (2-5 y)
respectively (median duration of follow up-3yrs.).
Discussion: In this small cohort of patients with FL and MCL
treated by R-chemotherapy, 100% of the harvested stem cell
products were tumor free by PCR analysis. Our ﬁndings
suggest that with universal use of rituximab containing
chemo-immunotherapy in patients with FL and MCL, addi-
tional in-vivo purging may not be required. We may also
conclude that persistence of residual/refractory disease afterTable 1
Patient Characteristics
Patient characteristics
Age (median and range) 59 y (41-64)
Sex (M:F) 17:2
Diagnosis (n)
Follicular lymphoma 15
Mantle cell lymphoma 4
Chemotherapy (n)
RICE 7
R-HyperCVAD 3
R-Bendamustine 5
R-CHOP 4
Status at transplantation (n)
CR1 4
CR2 3
>CR2 2
PR (Chemo sensitive) 2auto SCT rather than tumor contamination of the graft was
the most likely cause of relapse in this cohort.
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Mobilization failure is seen in 10-15% of patients undergoing
G-CSF or chemo mobilization and the use of plerixafor is
limited by its cost in developing countries. This phase II study
is being undertaken to study whether the addition of
Meloxicam to standard G-CSF will improve rates of mobili-
zation (CTRI/2014/06/004671). Patients received Meloxicam
15mg once daily for 5 days from Day -7 to -3 and G-CSF 5 mg/
kg BD from Day -4 to -1. Target CD34 dose was 4 x 106 CD34/
Kg. Patients with myeloma proceeded immediately to an
autologous transplant (auto SCT) with single agent
melphalan conditioning while patients with lymphoma and
AML had cryopreservation of harvest followed by using
either BEAM or BuCy2 conditioning.
Between November 2013 and July 2014, 25 patients
(20 males and 5 females) with a median age of 51 years
(range: 25-63) received meloxicamwith G-CSF. There was no
toxicity in any of the patients during the 5 days of adminis-
tration of meloxicam. A cell dose of > 2 x 106 CD34/kg was
achieved in 21 (84%) with a cell dose of > 3 x 106 CD34/kg
being achieved in a single harvest in 15 (60%). Four patients
needed additional cyclophosphamide mobilization to
achieve the target cell doses. Analysis of peripheral blood
CD34 counts revealed that 20 (80%) had counts > 20/ul onAPML/AML 2 (8%) 4 (8%)
Successful mobilization (>2 
106 CD34/kg after 2 harvests)
21 (84%) 42 (84%) 1.000
CD34 > 5  106/kg 12 (48%) 18 (36%) .138
CD34 > 3  106/kg 20 (80%) 32 (64%) .191
Conditioning regimen
High dose melphalan 15 (60%) 32 (64%)
BEAM 8 (32%) 14 (28%)
Bu/Cy2 2 (8%) 4 (8%)
ANC > 500/cumm (d) 11.09  0.53 11.53  0.92 .044
ANC > 1000/cumm (d) 11.61  0.45 11.95  0.99 .216
Platelet count > 20000/cumm (d) 14.7  4.5 16.4  6.3 .291
Platelet count > 50000/cumm (d) 17.4  7.5 24.7  19.3 .143
Platelet count> 100000/cumm (d) 23.1  11.9 51.2  58.2 .025
Number of red cell units
transfused
1.19  1.1 2.31  2.45 .031
Number of platelet units
transfused
12  9.1 17  16 .327
No of pts with grade III-IV toxicity 7/21 (31.8%) 33/47 (59.5%) .040
Duration of hospital stay from
day 0 (d)
16  3.3 20  7.3 .025
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these 15 (60%) had achieved counts of> 20/ul on Day -1 itself
[median count of 45.3/ul (range: 21.4e130.2)]. None of the
patients had toxicity related to meloxicam. Subsequently 21
patients underwent auto SCT and their data was compared
with 50 age and disease matched controls who had
mobilization and auto SCT at our center between January
2013 and March 2014. Though mobilization rates and cell
doses were not signiﬁcantly different, the use of meloxicam
and G-CSF was associated with faster neutrophil engraft-
ment. Following auto SCT, there was lower Grade IIIeIV
toxicity, lower transfusion requirement of red cells and
reduction in the duration of hospital stay post SCT [Table 1].
Conclusion: The addition of meloxicam to G-CSF improves
stem cell mobilization and is associated with faster engraft-
ment, no additional toxicity, lower supportive care and lower
duration of hospitalization. It is also potentially possible that
we may be able to harvest the patients a day earlier
depending upon the peripheral blood CD 34 counts achieved.
This datawarrants a prospective randomized trial comparing
Meloxicam + G-CSF with G-CSF alone as a mobilization
strategy prior to autologous stem cell transplantation.Table 1
Vascath (15) CVL (12) p-value
Diagnosis
Neuroblastoma/
Ganglioneuroblastoma
8 7
CNS tumor 3 4
Retinoblastoma 1 0
Lymphoma 2 1
Ewing’s Sarcoma 1 0
Mean # pheresis days 1.2 (1-3) 1.3 (1-2) 0.62
Median weight (kg) 22 (10-120.9) 15.4 (7.45-45.6) 0.06
Median peripheral
blood absolute CD34
count day 1
206 (35.6-766) 354 (12.8-928) 0.5
Median CD34/kg
collected (X 106)
21.5 (6.5-111) 46.7 (13.3-101) 0.06
Median time from admit
to pheresis start
(minutes)
333 (190-607) 179 (80-453) 0.0002
Median total time on
machine (minutes)
245 (121-851) 281 (180-582) 0.3
Mean inlet ﬂow rate
(ml/min)
70.1 (15.9-128.5) 25.5 (9.8-54) 0.002
Mean inlet ﬂow rate/kg 1.56 (0.7-3.95) 2.22 (1.18-2.06) 0.03
Mean # pressure/ﬂow
error readings
0.6 (0-6) 2.4 (0-5) 0.01153
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Background: Early (<12 months from diagnosis) autologous
stem cell transplantation (ASCT) remains a standard treat-
ment for eligible patients with multiple myeloma (MM).
However studies suggest comparable overall survival (OS)
outcomes in patients undergoing delayed (>12 months from
diagnosis) ASCT. Little is known about the outcomes upon
relapse from a delayed ASCT and hence we describe the
natural course of the disease and identify factors that predict
post-ASCT relapse survival in this group of patients.
Patients and Methods: We examined the outcomes of 207
MM patients who underwent a delayed ASCT (12 or more
months from their initial diagnosis) at the Mayo Clinic,
Rochester and then relapsed between 2000 and 2012. Pa-
tients who received a tandem or an allogeneic stem cell
transplant post ﬁrst ASCT were not included in this study.
Multivariate analysis was performed using a Cox propor-
tional hazards model.
Results: Median (range) age at ASCT and at relapse was 62
yrs (40-75) and 63 yrs (40-76) respectively. The median time
to ASCT from MM diagnosis was 30 mos (12-202) and the
median time to relapse post-ASCT was 11 mos (2-100). The
median follow-up (95% CI) from relapse was 78 mos (60-99).
The median (range) number of regimens prior to ASCT was 2
(1-6). Of the 112 patients who had FISH testing at diagnosis,
30% were categorized as high risk. The median (95% CI) LDH
and plasma cell labeling index at diagnosis was 169
(178e215) and 0.6 (1e1.5) respectively. The median (95% CI)
post-ASCT relapse survival (PRS) and overall survival from
diagnosis was 30 (22-36) and 77 (69-87) mos, respectively.
The distribution (N, %) of the post-relapse treatment regi-
mens were as follows: immunomodulator-based (103, 50%),
proteasome inhibitor-based (47, 23%), non-novel agent
chemotherapy (31, 15%), novel investigational therapy (22,
11%) and repeat ASCT (4, 1%). In a multivariate analysis, only
shorter time to relapse, presence of CRAB symptoms orextramedullary disease at relapse, higher pre-ASCT plasma
cell labeling index and LDH predicted for a shorter PRS. The
presence of high-risk cytogenetics by FISH, and choice of
salvage therapy upon relapse post-ASCT did not affect PRS in
the multivariable model.
Conclusion: MM patients who undergo a delayed ﬁrst ASCT
experience improved PRS if they have a longer duration of
response to ASCT, lack CRAB symptoms or extramedullary
disease at relapse (only biochemical progression) and have a
lower pre-ASCT plasma cell labeling index and serum LDH.
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Background and Methods: Large bore venous catheters
such as Vas-cath or hemodialysis catheters are recom-
mended for stem cell pheresis but rarely placed for routine
chemotherapy requiring placement of a second line for
pheresis. Timing pheresis with count recovery and stem cell
collection can be logistically challenging. Due to these chal-
lenges and desire to avoid additional line placement and
anesthesia, we attempted to use double lumen central
venous lines (CVL) for stem cell pheresis in patients who had
them at the time of referral.
Results: Twenty-seven patients underwent stem cell phe-
resis for autologous stem cell transplant from January 2012
to October 2014 utilizing a Cobe Spectra. Patient character-
istics and results (as means/medians and ranges) are detailed
in Table 1. Double lumen CVL was used preferentially for
stem cell pheresis if there was one placed at diagnosis for
chemotherapy and present at time of referral. Thirteen
patients referred for stem cell pheresis had double lumen
CVL (usually 7-9 Fr double lumen Broviacs). The remaining
fourteen patients had either no central line or had
